AC BioScience is thrilled to announce the success of its application to the highly competitive Eurostars program. Eurostars forms part of the European Union's funding program for SMEs for multi-partner transnational innovation projects. AC BioScience is the lead partner of a consortium that includes the Luxembourg Institute of Health (LIH) and Gustave Roussy Institute (IGR, France).
This European grant disbursed through Innosuisse will allow AC BioScience to accelerate the preclinical development of its immuno-stimulatory lead molecule ACB1801. This molecule strongly increases the class-I antigen presentation and potentiates anti PD-1 efficacy in experimental models. It will be proposed for the treatment of MSI-L/MSS colorectal cancer patients in clinical trials in combination with the anti PD-1 pembrolizumab.